- Home
- RARE vs WB Comparison
RARE vs WB Comparison
Compare RARE & WB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- WB
- Stock Information
- Founded
- RARE 2010
- WB 2009
- Country
- RARE United States
- WB China
- Employees
- RARE N/A
- WB N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- WB Computer Software: Programming Data Processing
- Sector
- RARE Health Care
- WB Technology
- Exchange
- RARE Nasdaq
- WB Nasdaq
- Market Cap
- RARE 3.2B
- WB 2.8B
- IPO Year
- RARE 2014
- WB 2014
- Fundamental
- Price
- RARE $33.00
- WB $10.74
- Analyst Decision
- RARE Strong Buy
- WB Buy
- Analyst Count
- RARE 15
- WB 2
- Target Price
- RARE $87.00
- WB $14.00
- AVG Volume (30 Days)
- RARE 1.4M
- WB 902.4K
- Earning Date
- RARE 11-04-2025
- WB 11-18-2025
- Dividend Yield
- RARE N/A
- WB 15.31%
- EPS Growth
- RARE N/A
- WB 9.65
- EPS
- RARE N/A
- WB 1.41
- Revenue
- RARE $630,598,000.00
- WB $1,762,960,000.00
- Revenue This Year
- RARE $19.65
- WB $0.82
- Revenue Next Year
- RARE $23.65
- WB $2.15
- P/E Ratio
- RARE N/A
- WB $7.64
- Revenue Growth
- RARE 20.63
- WB 1.37
- 52 Week Low
- RARE $25.81
- WB $7.10
- 52 Week High
- RARE $53.04
- WB $12.96
- Technical
- Relative Strength Index (RSI)
- RARE 52.70
- WB 40.06
- Support Level
- RARE $29.36
- WB $10.30
- Resistance Level
- RARE $35.95
- WB $10.85
- Average True Range (ATR)
- RARE 1.60
- WB 0.22
- MACD
- RARE -0.36
- WB -0.02
- Stochastic Oscillator
- RARE 60.79
- WB 33.20
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About WB Weibo Corporation
Weibo Corp is a China-based company mainly engaged in the social media advertising business for people to create, discover and distribute content. The company's activities include Advertising and Marketing, which mainly provides a full range of advertising customization and marketing solutions. The Value-added Services mainly provide services such as membership services on social platforms, online games, live broadcasts, social e-commerce, and others. The Company's main product is the social platform Weibo.